ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

587
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
03 Apr 2022 11:10

Hong Kong Connect Flows: CNOOC, Wuxi Biologics, JD.com

We highlight weekly southbound inflows from mainland China into CNOOC, Wuxi Biologics and outflows from JD.com after dividend in specie.

Logo
281 Views
Share
27 Mar 2022 11:39

Hong Kong Connect Flows: What Chinese Bought for Rebound?

We highlight weekly Hong Kong Connect sound bound inflows into Li Ning, Wuxi Biologics, HKEx, and China Mobile. We also noticed huge southbound...

Logo
330 Views
Share
bullishCelltrion Inc
21 Mar 2022 17:32

Celltrion and Celltrion Health Placement - Past Deals Have Been Mixed

Temasek aims to raise around US$450m+ via selling 1.7% of Celltrion Inc (068270 KS) and Celltrion Healthcare (091990 KS) each.

Logo
465 Views
Share
06 Mar 2022 10:32

Hong Kong Connect Flows: Tencent, Meituan, CNOOC, Wuxi Biologics

We highlight weekly HK Connect inflows into Tencent, Meituan, Cnooc, Wuxi Biologics, and outflows from HKEx, GWM, and Sunny Optical.

Logo
387 Views
Share
25 Feb 2022 06:15

Greater China Funds: China Health Care Reversal

Greater China managers have actively rebalanced portfolios away from China & HK Health Care over the last 6-months, with Taiwan Tech the key...

Logo
399 Views
Share
x